Table of Contents for Emotional and Behavioral Disorders in Children and Adolescents
|
INTRODUCTION |
XXIV |
|
STUDY OBJECTIVES |
XXIV |
|
REASONS FOR DOING THIS STUDY |
XXIV |
|
CONTRIBUTIONS OF THE STUDY |
XXV |
|
SCOPE OF THE STUDY |
XXV |
|
METHODOLOGY |
XXVI |
|
INFORMATION SOURCES |
XXVI |
|
ABOUT THE AUTHOR |
XXVI |
|
RELATED BCC REPORTS |
XXVI |
|
BCC ONLINE SERVICES |
XXVII |
|
DISCLAIMER |
XXVII |
|
SUMMARY |
XXVIII |
|
Summary Table: |
XXVIII |
|
Summary Figure: |
XXIX |
|
OVERVIEW |
1 |
|
DEFINITIONS OF EMOTIONAL AND/OR BEHAVIOR DISORDERS |
1 |
|
DEFINITIONS OF EMOTIONAL AND/OR…(CONTINUED) |
2 |
|
TERMINOLOGY |
3 |
|
CLASSIFICATION OF EMOTIONAL AND BEHAVIORAL DISORDERS |
3 |
|
Table 1 DSM CLASSIFICATIONS* OF EMOTIONAL AND BEHAVIORAL DISORDERS |
4 |
|
Table 2 CLASSIFICATION OF EMOTIONAL AND BEHAVIORAL DISORDERS (AS DONE FOR THIS REPORT) |
5 |
|
CAUSES OF EMOTIONAL AND BEHAVIOR DISORDERS |
6 |
|
BIOLOGICAL FACTORS |
6 |
|
PSYCHOPHYSIOLOGICAL AND GENETIC INFLUENCES |
7 |
|
NEUROLOGICAL DYSREGULATION |
7 |
|
ENVIRONMENTAL FACTORS |
7 |
|
SCHOOL-RELATED FACTORS |
8 |
|
PARENT PSYCHOLOGICAL FACTORS |
8 |
|
FAMILIAL CONTRIBUTIONS |
8 |
|
Divorce, Marital Distress and Violence |
9 |
|
Family Adversity and Insularity |
9 |
|
Parent-child Interactions |
10 |
|
Other Family Characteristics |
10 |
|
CHARACTERISTICS OF STUDENTS WITH BEHAVIOR DISORDERS |
10 |
|
INTELLIGENCE AND ACHIEVEMENT |
10 |
|
Social Skills and Interpersonal Relationships |
10 |
|
Antisocial Behavior |
10 |
|
Withdrawn Behavior |
11 |
|
MANIFESTATIONS OF BEHAVIOR DISORDERS |
11 |
|
TYPES OF DISORDERS |
12 |
|
ANXIETY DISORDERS |
12 |
|
TYPES OF ANXIETY DISORDERS |
12 |
|
CAUSES |
13 |
|
SYMPTOMS AND TREATMENT |
13 |
|
Psychological Treatments |
14 |
|
Psychopharmacological Treatments |
14 |
|
Environmental Treatments |
15 |
|
SEVERE DEPRESSION |
15 |
|
CAUSES |
16 |
|
SYMPTOMS AND TREATMENT |
16 |
|
Symptoms and Treatment (Continued) |
17 |
|
BIPOLAR DISORDER |
18 |
|
SYMPTOMS AND TREATMENT |
19 |
|
Symptoms and Treatment (Continued) |
20 |
|
ATTENTION DEFICIT HYPERACTIVITY DISORDER |
21 |
|
SYMPTOMS AND TREATMENT |
22 |
|
AUTISM |
23 |
|
SYMPTOMS AND TREATMENT |
24 |
|
SCHIZOPHRENIA |
25 |
|
SYMPTOMS AND TREATMENT |
25 |
|
LEARNING DISORDERS |
26 |
|
SYMPTOMS AND TREATMENT |
26 |
|
CAUSES |
27 |
|
CONDUCT DISORDER |
27 |
|
SYMPTOMS AND TREATMENT |
28 |
|
EATING DISORDERS |
29 |
|
SYMPTOMS AND TREATMENTS |
30 |
|
DRUG CLASSIFICATION |
31 |
|
CLASSIFICATION BASED ON MECHANISM OF ACTION |
31 |
|
BENZODIAZEPINES |
31 |
|
Table 3 BENZODIAZEPINES |
31 |
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) |
32 |
|
Table 4 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) |
32 |
|
TRICYCLIC ANTIDEPRESSANTS |
32 |
|
Table 5 TRICYCLIC ANTIDEPRESSANTS |
32 |
|
ANTIHISTAMINES |
33 |
|
Table 6 ANTIHISTAMINES |
33 |
|
MAJOR TRANQUILIZERS OR NEUROLEPTICS |
33 |
|
Table 7 MAJOR TRANQUILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS |
33 |
|
MOOD STABILIZERS |
34 |
|
Table 8 MOOD STABILIZERS |
34 |
|
CNS STIMULANTS |
35 |
|
Table 9 CNS STMULANTS |
35 |
|
NONSTIMULANTS |
35 |
|
Table 10 NONSTMULANTS |
35 |
|
ATYPICAL ANTIPSYCHOTICS |
35 |
|
Table 11 ATYPICAL ANTIPSYCHOTICS |
36 |
|
CLASSIFICATION BASED ON THERAPEUTIC CATEGORY |
36 |
|
ANTIANXIETY DRUGS |
36 |
|
Table 12 DRUGS USED FOR ANTIANXIETY DISORDERS |
36 |
|
Table 12 (CONTINUED) |
37 |
|
Clorazepate |
37 |
|
Chlordiazepoxide |
37 |
|
Chlorpromazine |
37 |
|
Clonezepam |
38 |
|
Diazepam |
38 |
|
Doxipine |
38 |
|
Fluoxetine Hydrochloride |
38 |
|
Fluphenazine |
39 |
|
Fluvoxamine Maleate |
39 |
|
Haloperidol |
39 |
|
Hydroxyzine |
39 |
|
Nortriptyline |
39 |
|
Oxazepam |
39 |
|
Sertraline Hydrochloride |
40 |
|
Thioridazine |
40 |
|
Thioxanthene |
40 |
|
Trifluperazine |
40 |
|
SEVERE DEPRESSION DRUGS |
40 |
|
Table 13 DRUGS USED FOR SEVERE DEPRESSION |
41 |
|
Amitryptyline |
41 |
|
Fluoxetine Hydrochloride |
41 |
|
Impramine |
41 |
|
Sertraline Hydrochloride |
42 |
|
BIPOLAR DISORDER DRUGS |
42 |
|
Table 14 DRUGS USED FOR BIPOLAR DISORDER |
42 |
|
Lithium |
42 |
|
Divalproex |
42 |
|
Carbamazepine |
43 |
|
ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) DRUGS |
43 |
|
Table 15 DRUGS USED FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER |
43 |
|
Amphetamines |
44 |
|
Dextroamphetamine |
44 |
|
Methylphenidate |
44 |
|
Pemoline |
44 |
|
Atomoxetine Hydrochloride |
44 |
|
AUTISTIC DISORDER DRUGS |
45 |
|
Table 16 DRUGS USED FOR AUTISTIC DISORDER TREATMENT |
45 |
|
Risperidone |
45 |
|
SCHIZOPHRENIA DRUGS |
45 |
|
Table 17 DRUGS USED FOR SCHIZOPHRENIA |
46 |
|
SAFETY, EFFICACY AND REGULATION |
47 |
|
SAFETY AND EFFICACY |
47 |
|
SAFETY AND EFFICACY (CONTINUED) |
48 |
|
Table 18 LABELLED USE AND APPROVED AGE FOR AGENTS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS |
49 |
|
REGULATORY ASPECTS |
49 |
|
REGULATORY ASPECTS (CONTINUED) |
50 |
|
REGULATORY ASPECTS (CONTINUED) |
51 |
|
Table 19 DRUGS RECEIVING A BOXED WARNING, OTHER PRODUCT LABELING CHANGES, AND A MEDICATION GUIDE PERTAINING TO PEDIATRIC SUICIDAL TENDENCIES |
52 |
|
DRUG APPROVALS |
52 |
|
Table 20 DEVICES AND IMPLANTS APPROVED BY THE FDA 2000-APRIL 2005 |
53 |
|
INDUSTRY STRUCTURE |
54 |
|
BEHAVIOR AND EMOTIONAL DISORDER DRUG INDUSTRY MARKET BY COMPANY |
54 |
|
ANTIANXIETY |
54 |
|
Table 21 MARKET SHARES OF MANUFACTURERS OF ANTIANXIETY AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%) |
54 |
|
Figure 1 MARKET SHARES OF MANUFACTURERS OF ANTIANXIETY AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%) |
55 |
|
Antidepressants |
55 |
|
Table 22 MARKET SHARES OF MANUFACTURERS OF ANTIDEPRESSANT AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%) |
56 |
|
Figure 2 MARKET SHARES OF MANUFACTURERS OF ANTIDEPRESSANT AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%) |
56 |
|
Bipolar Disorders |
56 |
|
Table 23 MARKET SHARES OF MANUFACTURERS PRODUCING DRUGS FOR BIPOLAR DISORDER TREATMENT, 2004 (%) |
57 |
|
Figure 3 MARKET SHARES OF MANUFACTURERS PRODUCING BIPOLAR DISORDER DRUGS, 2004 (%) |
57 |
|
ADHD Disorders |
57 |
|
Table 24 MARKET SHARES OF MANUFACTURERS PRODUCING ADHD DRUGS FOR TREATING BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%) |
58 |
|
Figure 4 MARKET SHARES OF MANUFACTURERS OF ADHD DRUGS FOR TREATING BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%) |
58 |
|
Autistic Disorders |
59 |
|
Table 25 MARKET SHARES OF MANUFACTURERS OF AUTISTIC DISORDER DRUGS, 2004 (%) |
59 |
|
Figure 5 MARKET SHARES OF MANUFACTURERS OF AUTISTIC DISORDER DRUGS, 2004 (%) |
59 |
|
Schizophrenia |
60 |
|
Table 26 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING SCHIZOPHRENIA, 2004 (%) |
60 |
|
Figure 6 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING SCHIZOPHRENIA, 2004 (%) |
60 |
|
Learning Disorders |
61 |
|
Table 27 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING LEARNING DISORDERS, 2004 (%) |
61 |
|
Figure 7 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING LEARNING DISORDERS, 2004 (%) |
62 |
|
Eating Disorders |
62 |
|
Table 28 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING EATING DISORDERS, 2004 (%) |
63 |
|
Figure 8 MARKET SHARES OF MANUFACTURERS OF DRUGS TO TREAT EATING DISORDERS, 2004 (%) |
63 |
|
Conduct Disorders |
63 |
|
Table 29 MARKET SHARES OF MANUFACTURERS OF CONDUCT DISORDER DRUGS, 2004 (%) |
64 |
|
Figure 9 MARKET SHARES OF MANUFACTURERS OF CONDUCT DISORDER DRUGS, 2004 (%) |
64 |
|
MARKET BY DRUG TYPES |
65 |
|
TOTAL MARKET SIZE |
65 |
|
Table 30 WORLDWIDE SALES OF DRUGS BY TYPE TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
65 |
|
Table 31 PROPORTION OF TYPES OF DRUGS BEING USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2004 |
66 |
|
Figure 10 PROPORTION OF TYPES OF DRUGS BEING USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2004 (%) |
66 |
|
SALES BY TYPE OF THERAPEUTIC CATEGORY |
67 |
|
BENZODIAZEPINES |
67 |
|
Table 32 WORLDWIDE SALES OF BENZODIAZEPINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
67 |
|
Figure 11 WORLDWIDE SALES OF BENZODIAZEPINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
68 |
|
SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) |
68 |
|
Table 33 WORLDWIDE SALES OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
69 |
|
Figure 12 WORLDWIDE SALES OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
70 |
|
TRICYCLIC ANTIDEPRESSANTS |
70 |
|
Table 34 WORLDWIDE SALES OF TRICYCLIC ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
71 |
|
Figure 13 WORLDWIDE SALES OF TRICYCLIC ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
71 |
|
ANTIHISTAMINES |
71 |
|
Table 35 WORLDWIDE SALES OF ANTIHISTAMINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
72 |
|
Figure 14 WORLDWIDE SALES OF ANTIHISTAMINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
72 |
|
MAJOR TRANQUILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS |
73 |
|
Table 36 WORLDWIDE SALES OF MAJOR TRANQILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
73 |
|
Figure 15 WORLDWIDE SALES OF MAJOR TRANQILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
74 |
|
MOOD STABILIZERS |
74 |
|
Table 37 WORLDWIDE SALES OF MOOD STABILIZERS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
75 |
|
Figure 16 WORLDWIDE SALES OF MOOD STABILIZERS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
75 |
|
CNS STIMULANTS |
75 |
|
Table 38 WORLDWIDE SALES OF CNS STIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
76 |
|
Figure 17 WORLDWIDE SALES OF CNS STIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
77 |
|
NONSTIMULANTS |
77 |
|
Table 39 WORLDWIDE SALES OF NONSTIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
78 |
|
Figure 18 WORLDWIDE SALES OF NONSTIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
78 |
|
ATYPICAL ANTIPSYCHOTICS |
78 |
|
Table 40 WORLDWIDE SALES OF ATYPICAL ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
79 |
|
Figure 19 WORLDWIDE SALES OF ATYPICAL ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
80 |
|
MARKET BY DISORDERS |
81 |
|
TOTAL MARKET SIZE |
81 |
|
Table 41 WORLDWIDE SALES OF DRUGS BY TYPE OF DISORDER TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
81 |
|
Table 42 PERCENTAGE SHARE OF GLOBAL MARKET FOR DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY DISORDER TYPE, 2004 (%) |
82 |
|
Figure 20 SHARES OF GLOBAL MARKET FOR DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY DISORDER TYPE, 2004 (%) |
82 |
|
SALES BY TYPE OF DRUGS |
83 |
|
ANTIANXIETY AGENTS |
83 |
|
Table 43 WORLDWIDE SALES OF ANTIANXIETY DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
84 |
|
Figure 21 WORLDWIDE SALES OF ANTIANXIETY DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
84 |
|
DRUGS USED TO TREAT DEPRESSION |
85 |
|
Table 44 WORLDWIDE SALES OF ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
85 |
|
Figure 22 WORLDWIDE SALES OF ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
86 |
|
DRUGS USED TO TREAT BIPOLAR DISORDER |
86 |
|
Table 45 WORLDWIDE SALES OF DRUGS TO TREAT BIPOLAR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
87 |
|
Figure 23 WORLDWIDE SALES OF DRUGS TO TREAT BIPOLAR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
87 |
|
ADHD DRUGS |
87 |
|
Table 46 WORLDWIDE SALES OF ADHD DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
88 |
|
Figure 24 WORLDWIDE SALES OF ADHD DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
89 |
|
AUTISTIC DISORDER DRUGS |
89 |
|
Table 47 WORLDWIDE SALES OF AUTISTIC DISORDER DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
90 |
|
Figure 25 WORLDWIDE SALES OF AUTISTIC DISORDER DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
90 |
|
SCHIZOPHRENIA DRUGS |
91 |
|
Table 48 WORLDWIDE SALES OF SCHIZOPHRENIA DRUGS TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
91 |
|
Figure 26 WORLDWIDE SALES OF SCHIZOPHRENIA DRUGS TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
92 |
|
DRUGS FOR LEARNING DISORDERS |
92 |
|
Table 49 WORLDWIDE SALES OF DRUGS USED TO TREAT LEARNING DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
92 |
|
Figure 27 WORLDWIDE SALES OF DRUGS USED TO TREAT LEARNING DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
93 |
|
DRUGS FOR EATING DISORDERS |
93 |
|
Table 50 WORLDWIDE SALES OF DRUGS USED TO TREAT EATING DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
93 |
|
Figure 28 WORLDWIDE SALES OF DRUGS USED TO TREAT EATING DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
94 |
|
CONDUCT DISORDER DRUGS |
94 |
|
Table 51 WORLDWIDE SALES OF DRUGS TO TREAT CONDUCT DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
94 |
|
Figure 29 WORLDWIDE SALES OF DRUGS TO TREAT CONDUCT DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
95 |
|
DEMOGRAPHICS |
96 |
|
OVERVIEW |
96 |
|
ANTIANXIETY AGENTS |
97 |
|
Table 52 DEMOGRAPHICS OF ANTIANXIETY DRUG USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
97 |
|
Figure 30 DEMOGRAPHICS OF ANTIANXIETY DRUG USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
98 |
|
ANTIDEPRESSANTS |
98 |
|
Table 53 DEMOGRAPHICS FOR ANTIDEPRESSANT DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
99 |
|
Figure 31 DEMOGRAPHICS FOR ANTIDEPRESSANT DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
100 |
|
BIPOLAR DISORDER DRUGS |
100 |
|
Table 54 DEMOGRAPHICS FOR BIPOLAR DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
101 |
|
Figure 32 DEMOGRAPHICS FOR BIPOLAR DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
101 |
|
ADHD DRUGS |
101 |
|
Table 55 DEMOGRAPHICS FOR ADHD DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
102 |
|
Figure 33 DEMOGRAPHICS FOR ADHD DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
103 |
|
AUTISTIC DISORDER DRUGS |
103 |
|
Table 56 DEMOGRAPHICS FOR AUTISTIC DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
104 |
|
Figure 34 DEMOGRAPHICS FOR AUTISTIC DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
104 |
|
SCHIZOPHRENIA DRUGS |
104 |
|
Table 57 DEMOGRAPHICS FOR DRUGS USED TO TREAT SCHIZOPHRENIA IN CHILDREN AND ADOLESCENTS, 2004 (%) |
105 |
|
Figure 35 DEMOGRAPHICS FOR DRUGS USED TO TREAT SCHIZOPHRENIA IN CHILDREN AND ADOLESCENTS, 2004 (%) |
105 |
|
LEARNING DISORDER DRUGS |
106 |
|
Table 58 DEMOGRAPHICS FOR LEARNING DISORDER DRUGS IN CHILDREN AND ADOLESCENTS, 2004 (%) |
106 |
|
Figure 36 DEMOGRAPHICS FOR LEARNING DISORDER DRUGS IN CHILDREN AND ADOLESCENTS, 2004 (%) |
107 |
|
EATING DISORDER DRUGS |
107 |
|
Table 59 DEMOGRAPHICS FOR EATING DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
108 |
|
Figure 37 DEMOGRAPHICS FOR EATING DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
108 |
|
CONDUCT DISORDER DRUGS |
108 |
|
Table 60 DEMOGRAPHICS FOR CONDUCT DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
109 |
|
Figure 38 DEMOGRAPHICS FOR CONDUCT DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) |
109 |
|
NEW DEVELOPMENTS |
110 |
|
NEW DEVELOPMENTS |
110 |
|
AstraZeneca |
110 |
|
Table 61 NEW DRUGS FROM ASTRAZENECA |
110 |
|
Bristol-Myers Squibb |
110 |
|
Table 62 NEW DRUGS FROM BRISTOL-MYERS SQUIBB |
111 |
|
Celgene |
111 |
|
Table 63 NEW DRUGS FROM CELGENE |
111 |
|
GlaxoSmithKline |
111 |
|
Table 64 NEW DRUGS FROM GLAXOSMITHKLINE |
111 |
|
Table 64 (CONTINUED) |
112 |
|
Johnson & Johnson |
112 |
|
Table 65 NEW DRUGS FROM JOHNSON & JOHNSON |
112 |
|
Merck |
112 |
|
Table 66 NEW DRUGS FROM MERCK |
112 |
|
Novartis |
113 |
|
Table 67 NEW DRUGS FROM NOVARTIS |
113 |
|
Pfizer |
113 |
|
Table 68 NEW DRUGS FROM PFIZER |
113 |
|
Roche |
113 |
|
Table 69 NEW DRUGS FROM ROCHE |
113 |
|
Sanolfi-Aventis |
114 |
|
Table 70 NEW DRUGS FROM SANOFI-AVENTIS |
114 |
|
Shire |
114 |
|
Table 71 NEW DRUGS FROM SHIRE |
114 |
|
Solvay |
114 |
|
Table 72 NEW DRUGS FROM SOLVAY |
114 |
|
Wyeth |
115 |
|
Table 73 NEW DRUGS FROM WYETH |
115 |
|
PATENTS |
116 |
|
PATENTS BY YEAR |
116 |
|
Table 74 ANNUAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2001-2005 |
116 |
|
Figure 39 TOTAL PATENTS FOR EMOTIONAL AND BEHAVIORAL DISORDER TREATMENTS IN CHILDREN AND ADOLESCENTS, 2001-2005 |
117 |
|
Figure 40 ANNUAL SHARE OF PATENTS FOR EMOTIONAL AND BEHAVIORAL DISORDER TREATMENTS IN CHILDREN AND ADOLESCENTS, 2001-2005 (%) |
117 |
|
PATENTS BY CATEGORY |
118 |
|
Table 75 TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005 |
118 |
|
Figure 41 TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005 |
118 |
|
Figure 42 SHARE OF TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005 (%) |
119 |
|
SIGNIFICANT PATENTS OF 2005 |
119 |
|
Table 76 SIGNIFICANT PATENTS FOR DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS, 2005 |
120 |
|
PATENTS BY COMPANY |
120 |
|
Table 77 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COMPANY, 2001-2005 |
121 |
|
Table 77 (CONTINUED) |
122 |
|
PATENTS BY COUNTRY |
122 |
|
Table 78 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COUNTRY, 2001-2005 (NUMBER OF PATENTS) |
122 |
|
Table 78 (CONTINUED) |
123 |
|
Figure 43 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COUNTRY, 2001-2005 (NUMBER OF PATENTS) |
123 |
|
Table 79 TRENDS OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2005-2001 |
124 |
|
Figure 44 TRENDS OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2001-2005 |
124 |
|
Figure 45 SHARE OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2001-2005 (%) |
125 |
|
PATENTS BY ASSIGNEE |
125 |
|
Table 80 NUMBER AND SHARE OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005 |
125 |
|
Figure 46 NUMBER OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005 (NUMBER OF PATENTS) |
126 |
|
Figure 47 SHARES OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005 (%) |
126 |
|
INTERNATIONAL ASPECTS |
127 |
|
TOTAL MARKET SIZE |
127 |
|
Table 81 REGIONAL SALES OF TREATMENTS FOR BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
127 |
|
REGIONAL SALES BY TYPE OF DISORDER |
127 |
|
ANTIANXIETY AGENTS |
127 |
|
Table 82 REGIONAL SALES OF ANTIANXIETY AGENTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
128 |
|
Figure 48 REGIONAL SALES OF ANTIANXIETY AGENTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
128 |
|
ANTIDEPRESSANTS |
129 |
|
Table 83 REGIONAL SALES OF ANTIDEPRESSANTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
129 |
|
Figure 49 REGIONAL SALES OF ANTIDEPRESSANTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
130 |
|
BIPOLAR DISORDER DRUGS |
130 |
|
Table 84 REGIONAL SALES OF BIPOLAR DISORDER DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
131 |
|
Figure 50 REGIONAL SALES OF BIPOLAR DISORDER DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
131 |
|
ADHD DRUGS |
131 |
|
Table 85 REGIONAL SALES OF ADHD DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
132 |
|
Figure 51 REGIONAL SALES OF ADHD DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
133 |
|
AUTISTIC DISORDER DRUGS |
133 |
|
Table 86 REGIONAL SALES OF AUTISTIC DISORDER DRUGS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
134 |
|
Figure 52 REGIONAL SALES OF ADHD DRUGS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
134 |
|
SCHIZOPHRENIA DRUGS |
134 |
|
Table 87 REGIONAL SALES OF DRUGS TO TREAT SCHIZOPHRENIC DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
135 |
|
Figure 53 REGIONAL SALES OF DRUGS TO TREAT SCHIZOPHRENIC DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
135 |
|
Learning Disorder Drugs |
136 |
|
Table 88 REGIONAL SALES OF LEARNING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) |
136 |
|
Figure 54 REGIONAL SALES OF LEARNING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) |
137 |
|
Conduct Disorder Drugs |
137 |
